Quantum Computing partners with INmune Bio on Alzheimer’s drug research
QUBT•Quantum Computing will work with INmune Bio to apply quantum optimization, AI and analytics to Alzheimer’s drug research. The project will use QCi’s Dirac-3S machine and clinical-trial and public biomedical data to identify potential indications, biomarkers, patient groups and disease targets for XPro.
1. Research collaboration
The project will analyze INmune Bio clinical-trial data alongside public biomedical datasets to identify new indications and biomarkers for XPro (XPro1595), and to prioritize patient groups and potential disease targets. The partners will benchmark quantum optimization results against conventional statistical and machine-learning methods to assess where quantum adds value. The engagement is QCi’s first commercial customer deal in pharma and biotech.
